Your session is about to expire
← Back to Search
RFA Knife for POEM in Esophageal Disorders
Study Summary
This trial is comparing two ways to do a Per Oral Endoscopic Myotomy (POEM) procedure, which is used to treat various esophageal disorders. They are comparing the standard monopolar ERBE knife to the bipolar Speedboat-RSD knife, and hypothesize that the bipolar knife will allow for efficient completion of the POEM procedure with less post procedural pain.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can legally agree to a POEM procedure for my condition.I am unable to give my consent for treatment.I am 18 years old or older.
- Group 1: Monopolar Electrocautery tool
- Group 2: Bipolar Electrocautery tool
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still vacancies in this experiment for participants?
"According to the details found on clinicaltrials.gov, this medical trial is currently looking for new participants. The study was initially posted February 22nd 2022 and has been modified through March 31st of that same year."
What is the aggregate amount of participants in this clinical trial?
"Affirmative. Clinicaltrials.gov records suggest that this trial is actively enrolling participants, having been posted on February 22nd 2022 and updated as of March 31st 2022. 84 patients are needed across 1 clinical site to complete the study."
Share this study with friends
Copy Link
Messenger